Yes, and shorter too. We are arguing apple and orange. You are saying no paper on neuvax showing antibodies response to HER2. I am saying an antibody response to the peptide, nonspecific , not recognizing the HER2 protein. I don't think you can generate an antibody response to a specific peptide using GMCSF is all I am saying.
Also. a couple of months prior, I asked Remy if ALL the patients have been screened for immuno-competency and the answer from the investigator was yes, all of them.
In all my 25 years of using peptides for immunization I have never had any peptide, long or short, which did not induce antibodies.
I wrote to Remy a couple of days earlier about performing antibodies test on the 70 recurrent patients and she replied she will pass the idea on to the investigators. It is very simple to do such a test and the antibodies only need to recognize the immunizing peptide by elisa , not the HER2 protein per se. It can be done in less than a day should the blood be available.
Lool at the bright side. Now everyone and their mother become aware of GALE's Neucax.
Moreover, if the IDMC does not think a reversal of the reversed data will yield a different outcome and recommendation why would they bother to ask for an investigation ?
I suspect there is a subset of patients the data of which is reversed by mistake (or intentionally after receiving a bribe from a shorty). It won't be hard to figure out by a simple antibodiy test. The antibodies do not even have to be able to detect HER2. All that is needed is an eisa test against Neuvax the peptide. A few hours work is all it take to find out who gets what treatment and if she has recurrent disease. .
I have discussed this with Remy and she promised to communicate the idea to the investigators.
Lin, if Neucax works as we all believe, it will show in the to be announced Roche combo trial results in October and again in December. All is not lost.
Somehow I suspect the shorts have a hand in this mess. The company should get the FBI involved to get the shorties which I think is less than subhuman,
lawsuits are coming. However the damage may be limited (180 million share x (2.1-0.35)) if Neuvax works. I also posted on the investor village board , hoping to get some discussion on the pending investigation .
I posted a lengthy analysis of why GALE 's net present value should be $119 with global sale throw in. That message was deleted somehow in a short few minutes.
I think a phase 3 is a must. How long will it take ? Probably a year after the completion of enrolment. The key is how long will it take for GALE to complete enrollment. At this point, I am not even sure how long before the management decide to START phase 3. Hopefully they will make a move after the go to completion of Neuvax is in hand.
Since your mother developed breast ca so young. you better check yourself and your daughter for genetic predisposition to the disease.
Galena Biopharma announced status of GALE-301
Jun 09, 2016
SAN RAMON, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the sad demise of FBP's parents. Both FBP's dad and mom died in a car accident yesterday on interstate highway 5 in California. As such, FBP is now an orphan.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the progress of the development of Galena’s product candidates, including GALE-301 and GALE-302, patient enrollment in our clinical trials, as well as other statements related to the progress and timing of our development activities, present or future licensing, collaborative or financing arrangements, expected outcomes with regulatory agencies, and projected market opportunities for product candidates or that otherwise relate to future periods. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under “Risk Factors” in Galena’s Annual Report on Form 10-K for the year ended December 31, 2015 and most recent Qua
small bioech is the life blood for the advancement of medicine. Joe Biden can do us all a favor if he focus cancer moonshione effort on these criminals.